Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Crizanlizumab-tmca is a selectin blocker humanized IgG2 kappa monoclonal antibody that binds to P-selectin. Crizanlizumab-tmca is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 448 amino acids, and 2 light chains each containing 218 amino acids, with a theoretical molecular weight of approximately 146 kDa.
ADAKVEO (crizanlizumab-tmca) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to slightly brownish-yellow solution for dilution and subsequent administration by intravenous infusion. Each 10 mL vial contains 100 mg crizanlizumab-tmca, citric acid (5.4 mg), polysorbate 80 (2 mg), sodium citrate (50.5 mg), sucrose (753.3 mg) and water for injection with a pH of 6.
ADAKVEO® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Administer ADAKVEO 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.
If a dose is missed, administer ADAKVEO as soon as possible. If ADAKVEO is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.
If ADAKVEO is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.
Physicians should reevaluate the treatment at least yearly, to assess individual patient’s response to treatment and consider discontinuing therapy with ADAKVEO if no perceived benefit is achieved.
ADAKVEO may be given with or without hydroxyurea.
ADAKVEO should be prepared and administered by a healthcare professional.
Volume (mL)= patient's body weight (kg) x prescribed dose  [5 mg/kg]/ concentration of ADAKVEO [10mg/mL]
Dilute ADAKVEO in 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a total volume of 100 mL for intravenous infusion as follows:
Administer ADAKVEO diluted solution as soon as possible. If not administered immediately, store the prepared solution either:
Injection: 100 mg/10 mL (10 mg/mL) as a clear to opalescent, colorless to slightly brownish-yellow solution in a single-dose vial.
ADAKVEO (crizanlizumab-tmca) injection is a sterile, clear to opalescent, colorless to slightly brownish-yellow solution for intravenous infusion supplied as:
Carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial NDC 0078-0883-61
The single-dose vial has a rubber stopper and an aluminum cap with a plastic flip-off disk. Each 10 mL vial is made of Type 1 glass.
Manufactured by: Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, New Jersey 07936. Revised: Jun 2024
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ADAKVEO was evaluated in the SUSTAIN trial [see Clinical Studies]. Eligible patients were diagnosed with sickle cell disease (any genotype, including HbSS, HbSC, HbS beta0-thalassemia, HbS beta+-thalassemia, and others). Patients received ADAKVEO 5 mg/kg (N = 66) or 2.5 mg/kg (N = 64) or placebo (N = 62) administered by intravenous infusion on Week 0, Week 2, and every 4 weeks thereafter. The safety evaluation below is limited to the patients who received the recommended dose of 5 mg/kg.
Among the 66 patients that received the recommended dose (5 mg/kg), 83% were exposed for 6 months or longer and 61% were exposed for approximately one year; forty-two (64%) patients were treated with ADAKVEO in combination with hydroxyurea.
Serious adverse reactions were reported in 2 patients (3%) treated with ADAKVEO 5 mg/kg; both reactions were pyrexia.
Two deaths (3%) occurred in the ADAKVEO 5 mg/kg treatment group. None of the deaths were considered to be related to ADAKVEO.
The most common adverse reactions (≥ 10%) were arthralgia, nausea, back pain, abdominal pain, pyrexia and diarrhea.
Table 1 summarizes the adverse reactions in the SUSTAIN trial.
Table 1: Adverse Reactions (≥ 10%) in Patients Receiving ADAKVEO With a Difference Between Arms of > 3% Compared to Placebo in SUSTAIN
| Adverse Reactions | ADAKVEO 5 mg/kg N = 66 % |
Placebo N = 62 % |
||
| All Grades % | Grade ≥ 3 % | All Grades % | Grade ≥ 3 % | |
| Arthralgia | 18 | 2 | 8 | 2 |
| Nausea | 18 | 0 | 11 | 2 |
| Back pain | 15 | 0 | 11 | 0 |
| Abdominal paina | 12 | 0 | 5 | 0 |
| Pyrexia | 11 | 12 | 7 | 0 |
| Diarrhea | 11 | 0 | 3 | 2 |
| aAbdominal pain: abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal tenderness. | ||||
Clinically relevant adverse reactions (all Grades) that were reported in less than 10% of patients treated with ADAKVEO included: oropharyngeal pain, vomiting, pruritus (pruritus and vulvovaginal pruritus), musculoskeletal chest pain, myalgia, infusion-site reaction (infusion-site extravasation, infusion-site pain, and infusion-site swelling), and infusion-related reaction.
The safety of ADAKVEO was also evaluated in the STAND trial [see Clinical Studies]. Eligible patients were diagnosed with sickle cell disease (any genotype, including HbSS, HbSC, HbS beta0-thalassemia, HbS beta+-thalassemia, and others). Patients received ADAKVEO 5 mg/kg (N = 84) or 7.5 mg/kg (N = 83) or placebo (N = 85) administered by intravenous infusion on Week 0, Week 2, and every 4 weeks thereafter. The safety evaluation below is limited to the patients who received the recommended dose of 5 mg/kg.
Among the 84 patients that received the recommended dose (5 mg/kg), 93% were exposed for approximately 6 months or longer and 88% were exposed for approximately one year; sixty-two (74%) patients were treated with ADAKVEO in combination with hydroxyurea.
Serious adverse reactions were reported in 2 patients (2%) treated with ADAKVEO 5 mg/kg and this reaction was pain. The most common adverse reactions (≥ 10%) were headache, nausea, fatigue, vomiting and oropharyngeal pain.
Table 2: Adverse Reactions (≥ 10%) in Patients Receiving ADAKVEO With a Difference Between Arms of > 3% Compared to Placebo in STAND
| Adverse Reactions | ADAKVEO 5 mg/kg N = 84 % |
Placebo N = 85 % |
||
| All Grades % | Grade ≥ 3 % | All Grades % | Grade ≥ 3 % | |
| Headache | 25 | 1 | 19 | 0 |
| Nausea | 17 | 0 | 9 | 0 |
| Fatiguea | 13 | 0 | 8 | 0 |
| Vomiting | 10 | 0 | 5 | 0 |
| Oropharyngeal pain | 10 | 0 | 4 | 0 |
| a Fatigue includes asthenia and malaise. | ||||
Clinically relevant adverse reactions (all Grades) that were reported in less than 10% of patients treated with ADAKVEO or events having a difference of less than 3% between ADAKVEO treatment arms and placebo included: diarrhea, pruritus, dizziness,, infusion-related reaction, infusion-site reaction.
ADAKVEO interferes with automated platelet counts (platelet clumping) in particular when blood samples are collected in tubes containing EDTA, which may lead to unevaluable or falsely decreased platelet counts. Run blood samples within 4 hours of blood collection or collect blood samples in tubes containing citrate. When needed, estimate platelet count via peripheral blood smear.
Included as part of the PRECAUTIONS section.
In the SUSTAIN clinical trial, infusion-related reactions (IRRs) (defined as occurring during/within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. In the STAND clinical trial, IRRs were observed in 6 (7%) patients treated with ADAKVEO 5 mg/kg.
IRRs presented most frequently as pain, nausea, vomiting, fatigue, dizziness, pruritis, diarrhea, and pyrexia. Some IRRs have required hospitalizations. The majority of these IRRs occurred during the first and second infusions.
Monitor for and advise patients to report signs and symptoms of IRRs. Discontinue ADAKVEO infusion for severe IRRs and institute appropriate medical care. Consider permanent discontinuation of ADAKVEO treatment in case of severe IRRs. Manage mild to moderate infusion-related reactions with temporary interruption of infusion, slowing the rate of infusion, symptomatic treatment (e.g., acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS), opioids, antihistamines, intravenous fluids, and/or oxygen therapy). For subsequent infusions, consider premedication and/or infusion rate reduction.
Exercise caution with corticosteroids in patients with sickle cell disease unless clinically indicated (e.g., treatment of anaphylaxis). Use of corticosteroids may increase the risk of complications such as acute chest syndrome and fat embolism.
Infusion-related reactions are sometimes indistinguishable from vaso-occlusive crisis (VOC) events. IRRs and VOCs may occur concomitantly and/or VOCs may occur as a consequence of an IRR.
Interference with automated platelet counts (platelet clumping) has been observed following administration of ADAKVEO, in particular, when blood samples were collected in tubes containing ethylenediaminetetraacetic acid (EDTA). Mitigation strategies are recommended [see DRUG INTERACTIONS].
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see WARNINGS AND PRECAUTIONS].
Advise patients to inform their healthcare provider that they are receiving ADAKVEO prior to any blood tests due to the potential interference with laboratory tests used to measure platelet counts [see WARNINGS AND PRECAUTIONS].
No carcinogenicity or genotoxicity studies have been conducted with crizanlizumab-tmca.
In the 26-week repeat-dose toxicity study, cynomolgus monkeys were administered crizanlizumab-tmca once every 4 weeks at doses up to 50 mg/kg (at least 13.1 times the human clinical exposure based on AUC in patients with sickle cell disease at 5 mg/kg once every 4 weeks). There were no adverse effects of crizanlizumab-tmca on male or female reproductive organs.
Based on data from animal studies, ADAKVEO has the potential to cause fetal harm when administered to a pregnant woman. In an animal reproduction study, intravenous administration of crizanlizumab-tmca to pregnant cynomolgus monkeys from the onset of organogenesis through delivery resulted in a non-dose related increased fetal loss (abortions/stillbirths) at doses approximately 2.8 times the exposure at the recommended clinical dose at 5 mg/kg/dose once every 4 weeks (see Data).
There are insufficient human data on ADAKVEO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. ADAKVEO should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population is approximately 14% and up to 43%, respectively. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
Women with sickle cell disease have an increased risk of adverse pregnancy outcomes for the mother and the fetus. Pregnant women are at greater risk for VOCs, pre-eclampsia, eclampsia, and maternal mortality. For the fetus, there is an increased risk for intrauterine growth restriction, preterm delivery, low birth weight, and perinatal mortality.
Animal Data
In an enhanced pre-and postnatal development study in cynomolgus monkeys, pregnant animals received intravenous doses of crizanlizumab-tmca at 10 and 50 mg/kg once every 2 weeks during the period of onset of organogenesis through delivery. No maternal toxicity was observed. Maternal exposures at doses of 10 and 50 mg/kg were between 2.8 and 16 times, respectively, the human clinical exposure based on area under the curve (AUC) in patients with sickle cell disease at 5 mg/kg/dose once every 4 weeks. There was an increase in fetal loss (abortions or still births) at both crizanlizumabÂtmca doses which was higher in the third trimester.
There were no effects on infant growth and development through 6-months postpartum that were attributable to crizanlizumab-tmca.
Measurable crizanlizumab-tmca serum concentrations were observed in the infant monkeys at postnatal Day 28, confirming that crizanlizumab crosses the placental barrier.
There is no data on the presence of crizanlizumab-tmca in human or animal milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to crizanlizumab-tmca are unknown.
The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for ADAKVEO and any potential adverse effects on the breastfed child from ADAKVEO or from the underlying maternal condition.
The safety and effectiveness of ADAKVEO for sickle cell disease have been established in pediatric patients aged 16 years and older. Use of ADAKVEO for sickle cell disease is supported by evidence from adequate and well-controlled studies in adults and pediatric patients (SUSTAIN trial). The SUSTAIN trial enrolled one pediatric patient treated with ADAKVEO 5 mg/kg aged 16 years old [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY, Clinical Studies].
The safety and efficacy of ADAKVEO in pediatric patients below the age of 16 years have not been established.
There were no ADAKVEO-treated patients 65 years of age and older in the clinical studies for sickle cell disease [see Clinical Studies]. Clinical studies of ADAKVEO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
No Information Provided
None.
Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab can also dissociate preformed P-selectin/PSGL-1 complex.
Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.
ADAKVEO resulted in a dose-dependent P-selectin inhibition (measured ex vivo) in patients with sickle cell disease and healthy volunteers.
The pharmacokinetics of crizanlizumab-tmca were evaluated in healthy volunteers and patients with sickle cell disease. The mean crizanlizumab-tmca Cmax, AUClast, or AUCinf increased disproportionally over the dose range of 0.2 to 8 mg/kg (0.04 to 1.6 times the approved recommended dosage) in healthy volunteers. In healthy volunteers administered the 5 mg/kg dose, the mean [coefficient of variation (CV%)] crizanlizumab-tmca Cmax, AUClast, or AUCinf were 0.16 (15.3%) mg/mL, 33.6 (12.6%) mg*hr/mL and 34.6 (13.1%) mg*hr/mL, respectively.
The mean (% CV) volume of distribution was 4.26 (25.1%) L after a single crizanlizumab-tmca 5 mg/kg intravenous infusion in healthy volunteers.
The mean (% CV) terminal elimination half-life (t½) of crizanlizumab-tmca was 10.6 (20.5%) days and the mean clearance was 11.7 (16.2%) mL/hr at 5 mg/kg doses in healthy volunteers. The mean (% CV) elimination t½ of crizanlizumab-tmca was 11.4 (31.5%) days during dosing interval in patients with sickle cell disease.
Crizanlizumab-tmca is expected to be metabolized into small peptides by catabolic pathways.
The effect of renal or hepatic impairment on the pharmacokinetics of crizanlizumab-tmca is unknown.
Hydroxyurea had no clinically meaningful effect on crizanlizumab-tmca pharmacokinetics in patients in clinical studies.
Immunogenicity
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ADAKVEO or of other crizanlizumab products.
The immunogenicity of ADAKVEO was evaluated using a validated bridging immunoassay for the detection of binding anti-crizanlizumab-tmca antibodies. In a single arm, open label multiple dose study, 0 of the 45 patients with sickle cell disease treated with ADAKVEO 5 mg/kg tested positive for treatment-induced anti-crizanlizumab-tmca antibodies. In a single-dose study in healthy subjects, 1 of the 61 (1.6%) evaluable subjects tested positive for a treatment-induced antiÂcrizanlizumab-tmca antibodies. No treatment induced anti-crizanlizumab-tmca antibodies were detected (0 of 84 patients) in a phase 3 study at 5 mg/kg over the 52 week time period (samples collected at baseline, weeks 3, 15, 19, 27 and 51). Therefore, no significant effect on pharmacokinetics or pharmacodynamics has been observed or is expected.
In the 26-week repeat-dose toxicity study, administration of crizanlizumab-tmca in cynomolgus monkeys at dose levels up to 50 mg/kg/dose once every 4 weeks resulted in inflammation of the vessels in multiple tissues in 2 out of 10 animals.
The efficacy of ADAKVEO was evaluated in patients with sickle cell disease in SUSTAIN [NCT01895361], a 52-week, randomized, multicenter, placebo-controlled, double-blind study. A total of 198 patients with sickle cell disease, any genotype (HbSS, HbSC, HbS/beta0-thalassemia, HbS/beta+-thalassemia, and others), and a history of 2-10 VOCs in the previous 12 months were eligible for inclusion. Patients were randomized 1:1:1 to ADAKVEO 5 mg/kg (N = 67), ADAKVEO 2.5 mg/kg (N = 66), or placebo (N = 65) administered over a period of 30 minutes by intravenous infusion on Week 0, Week 2, and every 4 weeks thereafter for a treatment duration of 52 weeks. Randomization was stratified by patients already receiving hydroxyurea (Y/N) and by the number of VOCs in the previous 12 months (2 to 4, 5 to 10).
Patients received ADAKVEO (with or without hydroxyurea) and were allowed to receive occasional transfusions and pain medications [i.e., acetaminophen, NSAIDs, and opioids] on an as needed basis.
Patients recruited in the study had complications associated with sickle cell disease and other comorbidities, including a history of acute chest syndrome (18%); pulmonary hypertension (8%); priapism (7%); psychiatric manifestations (25%), including depression and anxiety; hypertension (17%); cholelithiasis (17%). Demographic and other baseline characteristics were similar among the treatment groups (see Table 3).
Table 3: Demographics and Baseline Characteristics in SUSTAIN Study
| ADAKVEO 5 mg/kg (N = 67) |
Placebo (N = 65) |
|
| Age (years) | ||
| Median | 29 | 26 |
| Range | 16, 63 | 16, 56 |
| Gender, n (%) | ||
| Male | 32 (48%) | 27 (42%) |
| Female | 35 (52%) | 38 (59%) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 20 (30%) | 11 (17%) |
| Not Hispanic or Latino | 45 (67%) | 53 (82%) |
| Unknown | 2 (3%) | 1 (2%) |
| Race | ||
| Black or African American | 60 (90%) | 60 (92%) |
| White | 4 (6%) | 3 (5%) |
| Other | 3 (5%) | 2 (3%) |
| Sickle cell disease genotype, n (%) | ||
| HbSS | 47 (70%) | 47 (72%) |
| HbSC | 9 (13%) | 8 (12%) |
| HbS/beta0 - thalassemia | 3 (5%) | 7 (11%) |
| HbS/beta+ - thalassemia | 7 (10%) | 1 (2%) |
| Other | 1 (2%) | 2 (3%) |
| Hydroxyurea use, n (%) | ||
| Yes | 42 (63%) | 40 (62%) |
| No | 25 (37%) | 25 (39%) |
| Number of VOCs in previous 12 months, n (%) | ||
| 2 to 4 | 42 (63%) | 41 (63%) |
| 5 to 10 | 25 (37%) | 24 (37%) |
| Abbreviation: VOCs, vasoocclusive crises. | ||
Efficacy was evaluated in the SUSTAIN study by the annual rate of VOCs leading to a healthcare visit. A VOC leading to a healthcare visit was defined as an acute episode of pain with no cause other than a vasoocclusive event that required a medical facility visit and treatment with oral or parenteral opioids, or parenteral NSAIDs. Acute chest syndrome, hepatic sequestration, splenic sequestration, and priapism (requiring a visit to a medical facility) were also considered VOCs.
Patients with sickle cell disease who received ADAKVEO 5 mg/kg had a lower median annual rate of VOC compared to patients who received placebo (1.63 vs. 2.98) which was statistically significant (p = 0.010). Reductions in the frequency of VOCs were observed among patients regardless of sickle cell disease genotype and/or hydroxyurea use.
Thirty-six percent (36%) of patients treated with ADAKVEO 5 mg/kg did not experience a VOC compared to 17% of placebo-treated patients. The median time to first VOC from randomization was 4.1 months in the ADAKVEO 5 mg/kg arm compared to 1.4 months in the placebo.
The main efficacy results of the pivotal study, SUSTAIN, are summarized in Table 4.
Table 4: Efficacy Results From SUSTAIN Trial in Sickle Cell Diseasea
| Event | ADAKVEO, 5 mg/kgb (n = 67) |
Placebob (n = 65) |
Treatment Difference Estimatec |
| Annual rate of VOCa | 1.63 | 2.98 | HL = -1.01, (-2.00, 0.00) |
| Annual rate of days hospitalized | 4 | 6.87 | |
| Abbreviations: HL, hodges-lehmann; VOC, vasoocclusive crises. aVOCs were as assessed by an independent review committee. bStandard median. cHL median difference [95% confidence interval (CI)]. |
|||
STAND
The efficacy of two doses of ADAKVEO, with or without HU/HC, was evaluated, but not established, in the STAND trial [NCT03814746], a randomized, placebo-controlled, double-blind, multicenter clinical study in adolescent and adult sickle cell disease patients with a history of VOCs. The efficacy results of STAND study are summarized in Table 6 below.
In this study, VOC was defined as a pain crisis (acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration were considered VOCs in this study.
A total of 252 sickle cell disease patients were randomized to the study, 85 in placebo arm, 84 in ADAKVEO 5 mg/kg arm and 83 in ADAKVEO 7.5 mg/kg arm. The 7.5 mg/kg ADAKVEO dose is not approved and is not recommended for use. Demographic and other baseline characteristics were similar among the treatment groups (see Table 5).
Table 5: Demographics and Baseline Characteristics in STAND Study
| ADAKVEO 5 mg/kg (N=84) |
Placebo (N=85) |
|
| Age (years) | ||
| Median | 24 | 25 |
| Range | 12, 64 | 12, 68 |
| Gender, n (%) | ||
| Female | 45 (54%) | 49 (58%) |
| Male | 39 (46%) | 36 (42%) |
| Race, n (%) | ||
| Black or African American | 46 (55%) | 43 (51%) |
| White | 27 (32%) | 26 (31%) |
| Asian | 6 (7%) | 6 (7%) |
| Other | 5 (6%) | 10 (12%) |
| Genotype, n (%) | ||
| HbSS | 58 (69%) | 58 (68%) |
| HbSC | 11 (13%) | 12 (14%) |
| HbS/beta+ - thalassemia | 8 (10%) | 8 (9%) |
| HbS/beta0 - thalassemia | 5 (6%) | 6 (7%) |
| Other | 2 (2%) | 1 (1%) |
| Ethnicity, n (%) | ||
| Not Hispanic or Latino | 54 (64%) | 57 (67%) |
| Hispanic or Latino | 22 (26%) | 18 (21%) |
| Other (not reported/unknown) | 8 (10%) | 10 (12%) |
| Hydroxyurea use, n (%) | ||
| Yes | 62 (74%) | 61 (72%) |
| No | 20 (24%) | 23 (27%) |
| Missing | 2 (2%) | 1 (1%) |
| Number of VOC leading to healthcare visit in the last 12 months, n (%) | ||
| <5 | 62 (74%) | 58 (68%) |
| ≥5 | 21 (25%) | 27 (32%) |
| Missing | 1 (1%) | 0 |
The percentages for subgroups of race and genotype donot add up to 100% due to rounding to 1 decimal place.The results of the efficacy analysis did not confirm the statistical superiority of ADAKVEO over placebo in reducing VOCs leading to a healthcare visit over the first-year post randomization.
Table 6. Efficacy Results from STAND Trial in Sickle Cell Disease
| Treatment | n | Adjusted annualized rate of VOC | (95% CI) | Between-treatment: comparison | ||
| Comparison | Rates ratio | (95% CI) | ||||
| Adakveo 5 mg/kg | 84 | 2.49 | (1.90, 3.26) | vs Placebo | 1.08 | (0.76, 1.55)* |
| Placebo | 85 | 2.3 | (1.75, 3.01) | |||
| n:Total number of participants included in the analysis. Obtained from fitting a negative binomial regression model with treatment and randomization stratification factors (baseline VOC and HU/HC) as covariates. The natural log of the observation period was used as offset. *The 95% CI includes 1, which indicates that the result is not statistically significant. |
||||||
ADAKVEO®
(ah dak vee oh)
(crizanlizumab-tmca) injection, for intravenous use
What is the most important information I should know about ADAKVEO?
ADAKVEO may cause serious side effects, including:
Tell your healthcare provider right away if you get any of the following signs or symptoms of an infusion-related reaction:
See “What are possible side effects of ADAKVEO?” for more information about side effects.
What is ADAKVEO?
ADAKVEO is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce how often painful crises happen.
It is not known if ADAKVEO is safe and effective in children under 16 years of age.
Before receiving ADAKVEO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive ADAKVEO?
What are the possible side effects of ADAKVEO?
ADAKVEO may cause serious side effects.
The most common side effects of ADAKVEO include:
These are not all of the possible side effects of ADAKVEO. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of ADAKVEO.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about ADAKVEO that is written for health professionals.
What are the ingredients in ADAKVEO?
Active ingredient: crizanlizumab-tmca
Inactive ingredients: citric acid, polysorbate 80, sodium citrate, sucrose, and water for injection
This Patient Information has been approved by the U.S. Food and Drug Administration.
